Lung Transplantation for Pulmonary Hypertension

ABSTRACT

Although lung transplantation is a viable option for patients with end-stage pulmonary hypertension, it is associated with numerous problems including infection, rejection, and limited long-term survival. Because of these limitations, transplantation should only be considered for patients who are failing maximal medical therapy. Treatment options for patients with pulmonary hypertension that may serve to prolong or obviate the need for transplantation include anticoagulation with warfarin, diuretics, and vasodilators such as calcium channel blockers or continuous intravenous epoprostenol (prostacyclin). The response to medical therapy should be assessed at regular intervals by evaluating exercise tolerance and hemodynamic parameters. Because waiting periods for transplantation now exceed 1.5 to 2 years in the United States, and the response to medications is unpredictable, referral for transplantation should occur when patients become symptomatic. Those who are responding well to medical therapy should be removed from the active transplant waiting list, whereas those who fail therapy should go on to transplant. Utilizing medical therapy and transplantation as complementary treatments will achieve the best potential to improve quality of life and prolong survival.

KEYWORD

Lung transplantation - prostacyclin - pulmonary hypertension

REFERENCES

• 1 Reitz B A, Wallwork J L, Hunt S A. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease.  N Engl J Med . 1982;  306 557-564
• 2 Rubin, L J, Nicod P, Hillis L D. Treatment of primary pulmonary hypertension with nifedipine.  Ann Intern Med . 1983;  99 433-438
• 3 Rich S, Brundage B H. High dose calcium channel blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary artery pressure and regression of right ventricular hypertrophy.  Circulation . 1987;  76 135-141
• 4 Rich S, Kaufmann E, Levy P S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.  N Engl J Med . 1992;  327(2) 76-81
• 5 Rubin L J, Mendoza J, Hood M. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial.  Ann Intern Med . 1990;  112 485-491
• 6 Higenbottam T W, Wells F, Wheeldon D. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin).  Lancet . 1984;  1 1046-1047
• 7 Conte J V, Gaine S P, Orens J B. Continuous intravenous prostacyclin as a bridge to lung transplantation.  J Heart Lung Transplant . 1998;  17 679-685
• 8 Rich S. Medical treatment of primary pulmonary hypertension: a bridge to transplantation?.  Am J Cardiol . 1995;  75(3) 63A-66A
• 9 Gaine S, Rubin L. Medical and surgical treatment options for pulmonary hypertension.  Am J Med Sci . 1998;  315(3) 179-184
• 10 Rich S. Executive summary of the World Symposium on PPH. Available at: http:www.who.int/ncd/cvd/pph.html. Accessed December 2000
• 11 Holcomb B W, Loyd J E, Ely E W. Pulmonary veno-occlusive disease: a case series and new observations.  Chest . 2000;  118(6) 1671-1679
• 12 Moser K M, Daily P O, Peterson K. Thromboendarterectomy for chronic, major vessel thromboembolic pulmonary hypertension: immediate and long-term results in 42 patients.  Ann Intern Med . 1987;  107 560-565
• 13 Rubin L J. Primary pulmonary hypertension.  N Engl J Med . 1997;  336(2) 111-117
• 14 Hopkins W E, Ochoa L L, Richardson. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome.  J Heart Lung Transplant . 1996;  15(1 Pt 1) 100-105
• 15 D'Alonzo G E, Barst R J, Ayres S M. Survival in patients with primary pulmonary hypertension: results from a national prospective registry.  Ann Intern Med . 1991;  115(5) 343-349
• 16 Rich S, Levy P S. Characteristics of surviving and nonsurviving patients with primary pulmonary hypertension.  Am J Med . 1984;  76 573-578
• 17 Rich S, Dantzker D R, Ayres S M. Primary pulmonary hypertension: a national prospective study.  Ann Intern Med . 1987;  107(2) 216-223
• 18 Kadikar A, Maurer J, Kesten S. The six-minute walk test: a guide to assessment for lung transplantation.  J Heart Lung Transplant . 1997;  16(3) 313-319
• 19 Fuster V, Steele P M, Edwards W D. Primary pulmonary hypertension: natural history and the importance of thrombosis.  Circulation . 1984;  70 580-587
• 20 Barst R J, Rubin L J, McGoon M D. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin.  Ann Intern Med . 1994;  121(6) 409-415
• 21 Shapiro S M, Oudiz R J, Cao T. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoerostenol infusion.  JACC . 1997;  30(2) 343-349
• 22 Gaine S. Pulmonary Hypertension.  JAMA . 2000;  284 3160-3168
• 23 Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive pulmonary disease: a clinical trial.  Ann Intern Med . 1980;  93 391-398
• 24 Barst R J, Rubin L J, Long W A. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group.  N Engl J Med . 1996;  334(5) 296-302
• 25 Badesch D B, Tapson V F, Mcgoon M D. A comparison of continuous intravenous epoprostenol with conventional therapy for pulmonary hypertension secondary to the scleroderma spectrum of diseases.  Ann Intern Med . 2000;  132(6) 425-434
• 26 Kuo P C, Johnson L B, Plotkin J S. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension.  Transplantation . 1997;  63(4) 604-606
• 27 Robbins I M, Gaine S P, Schilz R. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus.  Chest . 2000;  117(1) 14-18
• 28 McLaughlin V V, Genthner D E, Panella M M. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series.  Ann Intern Med . 1999;  4(130[9]) 740-743
• 29 Rosenzweig E, Kerstein D, Barst R. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects.  Circulation . 1999;  13(99[14]) 1858-1865
• 30 Sandoval J, Gaspar J, Pulido T. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension: a therapeutic alternative for patients nonresponsive to vasodilator treatment.  J Am Coll Cardiol . 1998;  32(2) 297-304
• 31 Rich S, Lam W. Atrial septostomy as palliative therapy for refractory primary pulmonary hypertension.  Am J Coll Cardiol . 1983;  51 1560-1561
• 32 Kerstein D, Levy P S, Hsu D T. Blade balloon atrial septostomy improves survival in patients with severe primary pulmonary hypertension.  Circulation . 1995;  91(7) 2028-2035
• 33 Rothman A, Sklansky M S, Lucas V W. Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension.  Am J Cardiol . 1999;  15(84(6)) 682-686
• 34 Rothman A, Beltran D, Kriett J M. Graded balloon dilation atrial septostomy as a bridge to lung transplantation in pulmonary hypertension [see comments].  Am Heart J . 1993;  125(6) 1763-1766
• 35 Tarver J H, Rosas I, Diette G B. Chronic ambulatory dopamine infusion therapy for refractory right heart failure due to pulmonary hypertension.  ARRCM . 2000;  161(3) A459
• 36 UNOS data. Available at: http://www.unos.org/frame_default.asp. Accessed October 2001
• 37 Lilienfeld D, Rubin L. Mortality from primary pulmonary hypertension in the United States, 1979-1996.  Chest . 2000;  117(3) 796-800
• 38 Maurer J R, Frost A E, Estenne M. International guidelines for the selection of lung transplant candidates.  J Heart Lung Transplant . 1998;  17(7) 703-709
• 39 Whyte R I, Robbins R C, Altinger J. Heart-lung transplantation for primary pulmonary hypertension.  Ann Thorac Surg . 1999;  67(4) 937-942
• 40 Bando K, Keenan R J, Paradis I L. Impact of pulmonary hypertension on outcome after single-lung transplantation.  Ann Thorac Surg . 1994;  58(5) 1336-1342
• 41 Bando K, Armitage J M, Paradis I L. Indications for and results of single, bilateral, and heart-lung transplantation for pulmonary hypertension.  J Thorac Cardiovasc Surg . 1994;  108(6) 1056-1065
• 42 Pasque M K, Trulock E P, Cooper J D. Single lung transplantation for pulmonary hypertension: single institution experience in 34 patients.  Circulation . 1995;  92 2252-2258
• 43 Hosenpud J D, Bennett L E, Keck B M, Boucek M M, Novick R J. The Registry of the International Society for Heart and Lung Transplantation: seventeenth official report-2000.  J Heart Lung Transplant . 2000;  19 909-931
• 44 Levine S MJ, Erikinson S G, Bryan C L. Ventilation-perfusion inequalities during graft rejection in patients undergoing single lung transplantation for primary pulmonary hypertension.  Chest . 1992;  101 401-405
• 45 1999 Annual Report of the U.S. Scientific Registry for Transplant Recipients and the Organ Procurement and Transplantation Network: Transplant Data: 1989-1998. Rockville, MD: U.S. Department of Health and Human Services, Health Resources and Services Administration, Office of Special Programs, Division of Transplantation; Richmond, VA: UNOS
• 46 Hosenpud J D, Bennett L E, Keck B M. The Registry of the International Society for Heart and Lung Transplantation: fourteenth official report-1997.  J Heart Lung Transplant . 1997;  16 691-712